Interface Biologics

Interface Biologics (IBI) develops novel biomedical polymer technologies that enhance the safety and effectiveness of implantable medical devices by reducing thrombosis, inhibiting infection and providing programmable delivery of pharmaceuticals and biologics. Endexo anti-thrombogenic technology encompasses a range of low molecular weight additives for reduced thrombus formation on devices without the use of heparin. Endexo is compatible with a wide-range of medical grade polymers and processing methods (ex. injection molding, solution spinning or extrusion). The additives self-migration properties introduce a permanent passive surface modification disturbing the adsorption of blood proteins and activation of platelets.